These EASL Clinical Practice Guidelines (CPGs) are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the optimal management of patients with acute and chronic HCV infections. These guidelines apply to therapies that are approved at the time of their publication.
Resources
Drug services professional
Around half of current injecting drug users will have hepatitis C, although this prevalence rate varies across the country. Find here tools, resources and other relevant documents to help drugs service staff raise awareness of hepatitis C amongst service users, and improve testing and access to care.
Showing 211 to 220 of 267 resources
-
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
UK, Rest of World 2014 Training, Reports & Research, Tools & Templates PDF -
Liver Disease: Today's Complacency, Tomorrow's Catastrophe. The All-Party Parliamentary Hepatology Group (APPHG) Inquiry into Improving Outcomes in Liver Disease
Out of disappointment at the persistent failure to develop a comprehensive approach to tackling liver disease, The All-Party Parliamentary Hepatology Group (APPHG) decided to conduct a comprehensive inquiry into the growing epidemic of liver disease. It invited evidence from Royal Colleges, clinicians, patients, charities, relevant industry figures, the NHS, Public Health England and the Government, in order to establish what needs to be done to improve outcomes for liver disease patients and save lives.UK 25 Mar 2014 Reports & Research PDF -
Hepatitis C Setting Standards in a Journey towards the Eradication of Infection and Disease as a Serious Health Issue in the EU
Initiatives which translate evidence and strategy into Hepatitis C Action are few and far between in the EU.UK, Rest of World 2014 Reports & Research, Strategy & Planning PDF -
New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access
This report summarises the current global treatment landscape for hepatitis C. The authors highlight 2014 as a 'turning-point in the history of the pandemic', but emphasise the detrimental impact of pharmaceutical company marketing strategies in making universal access to treatment practically unachievable. Suggestions for improving treatment access are put forth based on an examination of the lessons learnt from the fight against HIV/AIDS.UK, Rest of World 2014 Reports & Research PDF -
Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care? A narrative systematic review of the evidence base
The burden of hepatitis C (HCV) treatment is growing, as is the political resolve to tackle the epidemic. Primary care will need to work more closely with secondary care to succeed in reducing the prevalence of chronic HCV. This paper, providing a narrative systematic review of six databases, aims to identify research relating to the provision of antiviral treatment for HCV in primary care.UK Dec 2013 Reports & Research PDF -
Charles Gore: A Call to HCV Action
A video call to action from Charles Gore, Executive Director of the Medicines Patent Pool, and ex-CEO of The Hepatitis C Trust, President of the World Hepatitis Alliance and HCV Action steering committee member.
UK, Rest of World 19 Nov 2013 Case study, Other Video -
Shooting Up: Infections among people who inject drugs in the UK 2012: An update November 2013
A Public Health England update on the 2012 report, looking at changing patterns of injecting drug use in England; injection of image and performance enhancing drugs; changing patterns of psychoactive drug injection; and providing an update on infections and behaviours, as well as making recommendations.England Nov 2013 Reports & Research PDF -
The Uncomfortable Truth. Hepatitis C in England: The State of the Nation
Around 160,000 people in England have chronic hepatitis C, a preventable and treatable blood-borne virus that can lead to potentially fatal cirrhosis or cancer of the liver if left untreated. However, barriers to diagnosis, effective referral and treatment mean that many of these people are undiagnosed, and an increasing number are developing potentially fatal end stage liver disease.England Oct 2013 Reports & Research PDF -
Hepatitis C in the UK - 2013 Report
The most recent 2013 national estimates suggest that around 215,000 individuals are chronically infected with hepatitis C (HCV) in the UK. It is acknowledged that both hospital episode statistics and death certification underestimate true numbers of admissions and deaths from HCV-related end-stage liver disease and liver cancer, but nonetheless both continue to rise in the UK.UK Jul 2013 Reports & Research PDF -
An audit of hepatitis C services in a representative sample of English prisons, 2013
This audit by Public Health England (PHE) and the Department of Health (DH) describes national best practice standards relating to hepatitis C services in prisons in England; compares hepatitis C services in a representative sample of 20 English prisons against these national best practice standards, and provides objective evidence and intelligence for commissioners and service providers to assist in the development and delivery of high quality hepatitis C services in prisons.England May 2013 Reports & Research PDF